1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 Aug 2024
Admin
News Article

Samsung Biologics Joins the Pharmaceutical Supply Chain Initiative as Supplier Partner

Overview

Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced today that the company has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.

Samsung Biologics

Samsung Biologics is the first Korean CDMO to participate in the PSCI, a group of pharmaceutical and healthcare companies that share a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain.
Samsung Biologics will commit to PSCI principles that address five areas of responsible business practice – ethics, labor, health & safety, environment, and management systems.

Partnership Expectations

Samsung Biologics expects the partnership to help further advance the company’s steadfast dedication to sustainable growth and strengthen its Environmental, Social, and Governance (ESG) management.
As part of its efforts to decarbonize and build more resilient supply chains, Samsung Biologics has been engaging suppliers as champion of the Supply Chains Working Group within the Sustainable Market Initiative’s Health Systems Task Force.

Words from the CEO: Samsung Biologics

“We are pleased to join the PSCI and hope to actively support collective actions to improve supply chain management,” said John Rim, CEO and President of Samsung Biologics.
“As part of our commitment to deliver safe, high-quality biomedicines, we will incorporate PSCI principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain, contributing to a healthier future.”

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture.
Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs.
To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604 KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180 KL biomanufacturing capacity.
Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe.
We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity.
As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!